Journey Medical (DERM) earnings

Journey Medical Corp· Health Care

Results to: Jun 2026
Latest analysed call: Jun 2026 (Q2 FY26)
Balance sheet to: Dec 2025

Company research is public. Sign in to keep your own companies, notes and cases.

Journey Medical earnings: last reported Wed, 12 Aug 2026, for the quarter ended Jun 2026.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

Metric	Value	Change	Basis	Period	Note
Revenue	18.5 $ million	+23.3% YoY	Quarterly, as filed	Quarter to Jun 2026	Revenue from operations as filed.
Operating margin	2.5 %	+21.6 pts YoY	Operating profit / revenue	Quarter to Jun 2026	For the quarter; a change is in percentage points.
Net profit	-0.31 $ million	—	Quarterly, as filed	Quarter to Jun 2026	Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown.

Source: Inve data from filed results (SEC filings) · to Jun 2026

Price

$5.13 −2.84% · −$0.15

Last close Oct 15, 2026 · US · USD

Performance −28.7% 1Y

1Y: $7.2 on 14 Oct 2025 → $5.13. High $9.26 (22 Jan 2026), low $4.39 (30 Mar 2026).

Previous close: $5.28
52-week range: $4.39 – $9.26
One year: −31.69%

Overview

Symbol: DERM
Sector: Health Care
Exchange: US
Currency: USD

Financials

What the filings say

Net profit, year on year: +92% (quarter to jun 2026 against jun 2025).

In $ million. Oldest period first.

Line item	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	15	14	13	15	18	16	16	19
Expenses	18	11	16	18	19	17	17	18
Operating profit	-3	2	-3	-3	-2	-0	-1	0
Operating margin	−19.8%	16.4%	−25.3%	−19.2%	−8.7%	−2.8%	−9.3%	2.5%
Other income	1	-1	-1	-1	-1	-1	-1	-1
Interest	1	1	1	1	1	1	1	1
Profit before tax	-2	2	-4	-4	-2	-1	-2	-0
Tax rate	—	—	—	−1.6%	—	0.0%	—	−5.0%
Net profit	-2	2	-4	-4	-2	-1	-2	-0
EPS ($ per share)	-0.12	—	-0.18	-0.16	-0.09	—	-0.08	-0.01

Source: Inve data · income statement, quarterly · to Jun 2026

In $ million. Oldest period first.

Line item	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Reserves	5	-39	-69	-72	-87	-98
Total liabilities	42	55	88	56	60	63
Total assets	52	97	105	77	80	95

Source: Inve data · balance sheet · to Dec 2025

In $ million. Oldest period first.

Line item	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from operations	5	-2	-14	5	-9	-12
Cash from investing	-1	-10	-20	-5	-15	—
Cash from financing	-0	53	16	-5	17	16
Net cash flow	3	41	-17	-5	-7	4
Capital expenditure	—	—	-20	-5	-15	—
Free cash flow	—	—	-34	0	-24	—

Source: Inve data · cash flow · to Dec 2025

Insider filings

11 filings between Apr 22, 2026 and Jul 1, 2026.

Open market

decisions to buy or sell

Nobody bought or sold DERM on the open market in this window. The filings below are 11 awards.

Compensation

not trading decisions

11: Award — granted as compensation

Latest filings (40)

Date	Insider	What	Shares	Value
Jul 1, 2026	Herskowitz Neil Director	Award	50,000	$0
Jul 1, 2026	Toledano Miranda Jayne Director	Award	50,000	$0
Jul 1, 2026	Smith Justin Adam Director	Award	50,000	$0
Jun 25, 2026	Toledano Miranda Jayne Director	Award	10,000	$0
Jun 25, 2026	ROSENWALD LINDSAY A MD Director	Award	10,000	$0
Jun 25, 2026	Pearce Michael Cooper Director	Award	10,000	$0
Jun 25, 2026	Herskowitz Neil Director	Award	10,000	$0
Jun 25, 2026	Smith Justin Adam Director	Award	10,000	$0
Apr 22, 2026	Maraoui Claude President & CEO	Award	49,277	$0
Apr 22, 2026	Benesch Joseph CFO	Award	28,907	$0
Apr 22, 2026	Alloush Ramsey Chief Operating Officer	Award	46,863	$0
Aug 25, 2025	Maraoui Claude President & CEO	Option exercise	1,250,000	$81.3K
Aug 25, 2025	Maraoui Claude President & CEO	Tax withheld	10,877	$81.3K
Aug 5, 2025	Herskowitz Neil Director	Award	20,000	$0
Aug 5, 2025	Pearce Michael Cooper Director	Award	20,000	$0
Aug 5, 2025	Toledano Miranda Jayne Director	Award	20,000	$0
Aug 5, 2025	Smith Justin Adam Director	Award	20,000	$0
Aug 5, 2025	ROSENWALD LINDSAY A MD Director	Award	50,000	$0
Jun 25, 2025	Pearce Michael Cooper Director	Award	7,173	$0
Jun 25, 2025	Herskowitz Neil Director	Award	7,173	$0
Jun 25, 2025	Smith Justin Adam Director	Award	7,173	$0
Jun 25, 2025	ROSENWALD LINDSAY A MD Director	Award	7,173	$0
Jun 25, 2025	Toledano Miranda Jayne Director	Award	7,173	$0
Jun 17, 2025	Maraoui Claude President & CEO	Award	49,277	$0
Jun 17, 2025	Benesch Joseph CFO	Award	28,907	$0
Jun 17, 2025	Alloush Ramsey Chief Operating Officer	Award	46,863	$0
May 2, 2025	Alloush Ramsey COO	Sale	2,857	$19.5K
May 2, 2025	Benesch Joseph CFO	Sale	2,409	$16.5K
May 2, 2025	Maraoui Claude President & CEO	Sale	4,834	$33.1K
Mar 11, 2025	Maraoui Claude President & CEO	Sale	49,271	$246.8K
Mar 7, 2025	Maraoui Claude President & CEO	Sale	14,905	$74.7K
Mar 6, 2025	Maraoui Claude President & CEO	Sale	25,551	$128.8K
Mar 5, 2025	Maraoui Claude President & CEO	Sale	18,147	$93.1K
Mar 4, 2025	Maraoui Claude President & CEO	Sale	28,901	$145.7K
Mar 3, 2025	Maraoui Claude President & CEO	Sale	23,508	$122.0K
Feb 21, 2025	Benesch Joseph CFO	Sale	1,365	$7.1K
May 1, 2024	Maraoui Claude President & CEO	Award	175,000	$0
May 1, 2024	Benesch Joseph CFO	Award	80,000	$0
Jan 3, 2024	Maraoui Claude President & CEO	Award	175,000	$0
Jan 3, 2024	Benesch Joseph CFO	Award	80,000	$0

Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.

Your own record

Start an Inve Case for Journey Medical Corp

Free account. Everything above stays public.

Write why you follow Journey Medical Corp and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

Create your Inve Case What an account adds

Keep reading